adalimumab-aaty (Yuflyma) vs infliximab-dyyb (Inflectra)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
infliximab-dyyb (Inflectra)
Marketed by Celltrion and partners
NCT02096861 · Phase 3 · completed
Randomized, double-blind Phase 3 non-inferiority trial of CT-P13 against originator infliximab in biologic-naive active Crohn's disease (n=220). The primary endpoint, CDAI-70 response at Week 6, met non-inferiority: the lower bound of the 95% CI (-16.9%) was above the -20% margin.
Next expected readout: December 2026 · NCT06064864 (registry estimate)
Reported efficacy
CDAI-70 response rate at Week 6: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin (met)
Result source: NCT02096861
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab-dyyb (Inflectra) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Endoscopic response (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Endoscopic response (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not reported
Endoscopic response (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not reported
Clinical remission (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not reported
Endoscopic response (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aaty (Yuflyma): no structured comparison results are available for Crohn's Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
NCT03789292 · Phase 3 · completed
This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).
Reported efficacy
American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)
Result source: NCT03789292
infliximab-dyyb (Inflectra)
Marketed by Celltrion and partners
NCT01217086 · Phase 3 · completed
PLANETRA was a randomized, double-blind trial of CT-P13 against Remicade in active rheumatoid arthritis on methotrexate (617 enrolled; 606 in the ITT analysis). The published primary endpoint, ACR20 response at week 30, showed equivalence: 60.9% vs 58.6% (95% CI -6% to 10%), inside the predefined ±15% margin.
ClinicalTrials.gov lists pharmacokinetic equivalence as the primary outcome; the peer-reviewed PLANETRA report states the primary endpoint was ACR20 response at week 30.
Reported efficacy
ACR20 response at week 30 (equivalence vs Remicade, margin ±15%): ACR20 response at week 30 (ITT, n=606): CT-P13 60.9% vs innovator infliximab (INX) 58.6%; 95% CI −6% to 10%, within the predefined equivalence margin - equivalence demonstrated. (met)
Result source: NCT01217086
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab-dyyb (Inflectra) |
|---|---|---|
| ACR20 | 82.7% vs 82.7%vs HumiraNCT03789292 | 60.9% vs 58.6%avs innovator infliximab (INX)NCT01217086 |
| ACR50 | —Not reported | —Not posted · NCT01217086 |
| ACR70 | —Not reported | —Not posted · NCT01217086 |
| DAS28-CRP remission | —Not reported | —Not posted · NCT01217086 |
| HAQ-DI, change | —Not reported | —Not posted · NCT01217086 |
| Modified Sharp score, change | —Not reported | —Not posted · NCT01217086 |
ACR20
- adalimumab-aaty (Yuflyma)
- 82.7% vs 82.7%vs HumiraNCT03789292
- infliximab-dyyb (Inflectra)
- 60.9% vs 58.6%avs innovator infliximab (INX)NCT01217086
ACR50
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not posted · NCT01217086
ACR70
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not posted · NCT01217086
DAS28-CRP remission
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not posted · NCT01217086
HAQ-DI, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not posted · NCT01217086
Modified Sharp score, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-dyyb (Inflectra)
- —Not posted · NCT01217086
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 4 of 4 rows · infliximab-dyyb (Inflectra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-aaty (Yuflyma) | infliximab-dyyb (Inflectra) |
|---|---|---|
| Dropout rate | 6.5%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | — |
| Discontinued due to AEs | 2.2%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | — |
| Serious AEs | —CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.7%Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 2%Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.3%Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | — |
| Most frequent reported AEs | upper respiratory tract infection 5.6% nasopharyngitis 5.2% injection site reaction 4.9% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 show 2 more resultsneutropenia 5% upper respiratory tract infection 3.3% urinary tract infection 3% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 neutropenia 5.3% alanine aminotransferase increased 4.6% leukopenia 4.6% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | — |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-aaty (Yuflyma)
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · infliximab-dyyb (Inflectra)'s landscape